CBD protected mice from acute liver injury by preventing the breakdown of a key mitochondrial protein

CBD at 2.5 and 5 mg/kg mitigated LPS/D-GalN-induced liver damage, suppressed inflammatory cytokines, reduced hepatocyte death, and inhibited oxidative stress. The mechanism involved CBD preventing the degradation of mitofusin-2 (MFN2) by disrupting the interaction between Parkin and MFN2. When MFN2 was knocked down, CBD's protective effects were abolished; when MFN2 was overexpressed, protective effects were restored.

In vivo LPS/D-GalN-induced acute liver injury mouse model treated with CBD. RAW264.7 macrophage cells for in vitro validation. siRNA knockdown, plasmid overexpression, and adeno-associated virus delivery used to confirm MFN2 as the critical mediator. Multiple assays including H&E staining, TUNEL, TEM, Western blot, Co-IP, and more.

Acute liver injury can rapidly progress to liver failure with high mortality. This study identifies a specific molecular mechanism for CBD's hepatoprotective effects, which could inform development of liver injury treatments.

This adds mechanistic depth to the growing literature on CBD's anti-inflammatory properties. Rather than just showing CBD reduces inflammation, it identifies the specific mitochondrial pathway (Parkin-MFN2) responsible, which could apply beyond liver injury.

Animal model of chemically-induced liver injury may not reflect all forms of human liver disease. CBD doses and routes of administration may not translate directly. No human data. Mechanism found in one cell type (macrophages) may not apply universally.